WuXi Biologics (Cayman) (HKSE:02269) Current Deferred Revenue : HK$0 Mil (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

WuXi Biologics (Cayman)'s current deferred revenue for the quarter that ended in Jun. 2024 was HK$0 Mil.

WuXi Biologics (Cayman) Current Deferred Revenue Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Current Deferred Revenue Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

Get a 7-Day Free Trial

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Current Deferred Revenue	Get a 7-Day Free Trial														-	-	-	-	-

WuXi Biologics (Cayman) Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Li Ge	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Brown Brothers Harriman & Co.	2502 Approved lending agent
Zhao Ning	2202 Interest of your spouse
Liu Xiaozhong	2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited	2201 Interest of corporation controlled by you
New Wuxi Life Science Limited	2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited	2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc.	2201 Interest of corporation controlled by you
Zhang Zhaohui	2401 A concert party to an agreement to buy shares
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

WuXi Biologics (Cayman) Headlines

No Headlines